Gepotidacin: A Potential First-In-Class Oral Antibiotic With Recent Positive Ph. III Data

gepotidacin

oral BID antibacterial Type II topoisomerase inhibitor Ph. III for uncomplicated UTIs from unbiased antibacterial screen + opt. ECCMID, April 2023 Glaxo (GSK), Stevenage, UK

Drug Hunter Team

gepotidacin, bacterial topoisomerase, oral BID antibacterial, Type II topoisomerase inhibitor, Ph. III for uncomplicated UTIs, from unbiased antibacterial screen + opt., ECCMID, April 2023, GLAXO (GSK), STEVENAGE, UK||||

Gepotidacin: A Potential First-In-Class Oral Antibiotic With Recent Positive Ph. III Data

gepotidacin

Other molecules you may be interested in